Early Use of Novel Biologics in Psoriatic Arthritis: An Evolving Standard of Care

Download All
Hear expert insights on when to use interleukin inhibitors in the course of psoriatis arthritis. Review key data on using these novel agents for DMARD-refractory disease with an on-demand expert presentation and focused commentary.
Vinod Chandran, MBBS, MD, DM, PhD

ClinicalThought

Axial manifestations are common in patients with PsA. How can we use the latest data on inhibition of IL-17A and IL-23 to better manage axial symptoms?

Vinod Chandran, MBBS, MD, DM, PhD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Released: January 11, 2021 Expired: January 10, 2022
Provided by Clinical Care Options
Contact Info

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Novartis Pharmaceuticals Corporation

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue